期刊
MOLECULAR AND CLINICAL ONCOLOGY
卷 7, 期 3, 页码 498-506出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/mco.2017.1342
关键词
neutrophil-to-lymphocyte ratio; inflammation; lung cancer; prognosis; meta-analysis
类别
资金
- Jilin Provincial Science and Technology Department [20150101176]
- National Health and Family Planning Commission of the People's Republic of China [ZX-07-C2016004]
- National Key Research and Development Program of China [2016YFC1303800]
Current evidence suggests that the neutrophil-to-lymphocyte ratio (NLR) may be a biomarker for poor prognosis in lung cancer, although this association remains controversial. Therefore, a meta-analysis was performed to evaluate the association between NLR and lung cancer outcome. A systematic literature search was performed through the PubMed, Embase and Cochrane Library data-bases (until July 30, 2016), to identify studies evaluating the association between NLR and overall survival (OS) and/or progression-free survival (PFS) among patients with lung cancer. Based on the results of this search, data from 18 studies involving 7,219 patients with lung cancer were evaluated. The pooled hazard ratio (FIR) suggested that elevated pretreatment NLR predicted poor OS [FIR=1.46, 95% confidence interval (CI): 1.30-1.64] and poor PFS (HR=1.42, 95% CI: 1.15-1.75) among patients with lung cancer. Subgroup analysis revealed that the prognostic value of NLR for predicting poor OS increased among patients who underwent surgery (HR=1.50, 95% CI: 1.21-1.84) or patients with early-stage disease (HR=1.64, 95% CI: 1.37-1.97). An NLR cut-off value of >= 4 significantly predicted poor OS (HR=1.56, 95% CI: 1.31-1.85) and PFS (HR=1.54, 95% CI: 1.13-1.82), particularly in the cases of small-cell lung cancer. Thus, the results of the present meta-analysis suggested that an elevated pretreatment NLR (e.g.,>= 4) may be considered as a biomarker for poor prognosis in patients with lung cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据